GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization

Pfizer’s TUKYSA shows major benefit in first-line maintenance for metastatic breast cancer

The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA

BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first

Bristol Myers Squibb unveils breakthrough Lymphoma data

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas

Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications

Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors

Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership

The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

Bayer reports promising results for low-dose pediatric MRI contrast agent

MRI is particularly valuable in pediatric care due to its non-invasive nature

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options